ISSN 1671-5411 CN 11-5329/R

Dear Colleagues,

Journal of Geriatric Cardiology (J Geriatr Cardiol, JGC) will launch a new website and adopt ScholarOne ManuscriptsTM system to manage the submission and peer review process from November 1, 2020. To review and check the status of your manuscripts submitted before November 2020, please visit...

more

Volume 17 Issue 12
Dec.  2020
Turn off MathJax
Article Contents
Xin SU, Xin DU, Shang-Xin LU, Chao JIANG, Jing DU, Shi-Jun XIA, Zhao-Jie DONG, Zhao-Xu JIA, De-Yong LONG, Cai-Hua SANG, Ri-Bo TANG, Nian LIU, Song-Nan LI, Rong BAI, Jian-Zeng DONG, Chang-Sheng MA. Catheter ablation for atrial fibrillation is associated with reduced risk of mortality in the elderly: a prospective cohort study and propensity score analysis. J Geriatr Cardiol 2020; 17(12): 740-749. doi: 10.11909/j.issn.1671-5411.2020.12.008
Citation: Xin SU, Xin DU, Shang-Xin LU, Chao JIANG, Jing DU, Shi-Jun XIA, Zhao-Jie DONG, Zhao-Xu JIA, De-Yong LONG, Cai-Hua SANG, Ri-Bo TANG, Nian LIU, Song-Nan LI, Rong BAI, Jian-Zeng DONG, Chang-Sheng MA. Catheter ablation for atrial fibrillation is associated with reduced risk of mortality in the elderly: a prospective cohort study and propensity score analysis. J Geriatr Cardiol 2020; 17(12): 740-749. doi: 10.11909/j.issn.1671-5411.2020.12.008

Catheter ablation for atrial fibrillation is associated with reduced risk of mortality in the elderly: a prospective cohort study and propensity score analysis

doi: 10.11909/j.issn.1671-5411.2020.12.008
More Information
  • Corresponding author:

    Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing, China. E-mails: duxinheart@sina.com (DU X)

    Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing, China. E-mails: chshma@vip.sina.com (MA CS)

  • Received Date: 2020-09-05
  • Accepted Date: 2020-12-09
  • Rev Recd Date: 2020-11-05
  • Available Online: 2020-12-28
  • Publish Date: 2020-12-26
  •  Background It is unclear whether catheter ablation (CA) for atrial fibrillation (AF) affects the long-term prognosis in the elderly. This study aims to evaluate the relationship between CA and long-term outcomes in elderly patients with AF. Methods Patients more than 75 years old with non-valvular AF were prospectively enrolled between August 2011 and December 2017 in the Chinese Atrial Fibrillation Registry Study. Participants who underwent CA at baseline were propensity score matched (1:1) with those who did not receive CA. The outcome events included all-cause mortality, cardiovascular mortality, stroke/transient ischemic attack (TIA), and cardiovascular hospitalization. Results Overall, this cohort included 571 ablated patients and 571 non-ablated patients with similar characteristics on 18 dimensions. During a mean follow-up of 39.75 ± 19.98 months (minimum six months), 24 patients died in the ablation group, compared with 60 deaths in the non-ablation group [hazard ratio (HR) = 0.49, 95% confidence interval (CI): 0.30-0.79, P = 0.0024]. Besides, 6 ablated and 29 non-ablated subjects died of cardiovascular disease (HR = 0.25, 95% CI: 0.11–0.61, P = 0.0022). A total of 27 ablated and 40 non-ablated patients suffered stroke/TIA (HR = 0.79, 95% CI: 0.48–1.28, P = 0.3431). In addition, 140 ablated and 194 non-ablated participants suffered cardiovascular hospitalization (HR = 0.84, 95% CI: 0.67–1.04, P = 0.1084). Subgroup analyses according to gender, type of AF, time since onset of AF, and anticoagulants exposure in initiation did not show significant heterogeneity. Conclusions In elderly patients with AF, CA may be associated with a lower incidence of all-cause and cardiovascular mortality.
  • loading
  • [1]
    Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998; 98: 946-952. doi: 10.1161/01.CIR.98.10.946
    [2]
    Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129: 837-847. doi: 10.1161/CIRCULATIONAHA.113.005119
    [3]
    Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27: 949-953. doi: 10.1093/eurheartj/ehi825
    [4]
    Di Carlo A, Bellino L, Consoli D, et al. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Europace 2019; 21: 1468-1475. doi: 10.1093/europace/euz141
    [5]
    Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J 2013; 34: 2746-2751. doi: 10.1093/eurheartj/eht280
    [6]
    Curtis AB, Rich MW. Atrial fibrillation in the elderly: mechanisms and management. Heart Rhythm 2007; 4: 1577-1579. doi: 10.1016/j.hrthm.2007.07.023
    [7]
    Desai Y, El-Chami MF, Leon AR, et al. Management of atrial fibrillation in elderly adults. J Am Geriatr Soc 2017; 65: 185-193. doi: 10.1111/jgs.14483
    [8]
    Dayer M, Hardman SM. Special problems with antiarrhythmic drugs in the elderly: safety, tolerability, and efficacy. Am J Geriatr Cardiol 2002; 11: 370-375. doi: 10.1111/j.1076-7460.2002.0069.x
    [9]
    Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2017; 20: e1-e160. http://pubmedcentralcanada.ca/pmcc/articles/PMC5634725/
    [10]
    Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs. medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019; 321: 1275-1285. doi: 10.1001/jama.2019.0692
    [11]
    Blomström-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs. antiarrhythmic medication on quality of life in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA 2019; 321: 1059-1068. doi: 10.1001/jama.2019.0335
    [12]
    Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018; 378: 417-427. doi: 10.1056/NEJMoa1707855
    [13]
    Blandino A, Toso E, Scaglione M, et al. Long-term efficacy and safety of two different rhythm control strategies in elderly patients with symptomatic persistent atrial fibrillation. J Cardiovasc Electrophysiol 2013; 24: 731-738. doi: 10.1111/jce.12126
    [14]
    Metzner I, Wissner E, Tilz RR, et al. Ablation of atrial fibrillation in patients ≥ 75 years: long-term clinical outcome and safety. Europace 2016; 18: 543-549. doi: 10.1093/europace/euv229
    [15]
    Bulava A, Hanis J, Dusek L. Clinical outcomes of radiofrequency catheter ablation of atrial fibrillation in octogenarians: 10-year experience of a one high-volume center. J Geriatr Cardiol 2017; 14: 575-581. http://pubmedcentralcanada.ca/pmcc/articles/PMC5641645/
    [16]
    Kautzner J, Peichl P, Sramko M, et al. Catheter ablation of atrial fibrillation in elderly population. J Geriatr Cardiol 2017; 14: 563-568. http://europepmc.org/abstract/MED/29144514
    [17]
    Lioni L, Letsas KP, Efremidis M, et al. Catheter ablation of atrial fibrillation in the elderly. J Geriatr Cardiol 2014; 11: 291-295.
    [18]
    Mikhaylov EN, Szili-Torok T, Lebedev DS. Percutaneous interventions in elderly patients with atrial fibrillation: left atrial ablation and left atrial appendage occlusion. J Geriatr Cardiol 2017; 14: 541-546. http://www.ixueshu.com/document/be6c862ae782c14144c8bd591f7526d1318947a18e7f9386.html
    [19]
    Du X, Ma C, Wu J, et al. Rationale and design of the Chinese Atrial Fibrillation Registry Study. BMC Cardiovasc Disord 2016; 16: 130. doi: 10.1186/s12872-016-0308-1
    [20]
    Dong JZ, Sang CH, Yu RH, et al. Prospective randomized comparison between a fixed '2C3L' approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation. Europace 2015; 17: 1798-1806. doi: 10.1093/europace/euv067
    [21]
    Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, pathophysiology, and rationale for therapy. Am J Cardiol 2003; 91: 2D-8D.
    [22]
    Diener HC, Hart RG, Koudstaal PJ, et al. Atrial fibrillation and cognitive function: JACC review topic of the week. J Am Coll Cardiol 2019; 73: 612-619. http://www.sciencedirect.com/science/article/pii/S0735109719345541
    [23]
    Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet 2016; 388: 806-817. doi: 10.1016/S0140-6736(16)31257-0
    [24]
    Lin YJ, Chao TF, Tsao HM, et al. Successful catheter ablation reduces the risk of cardiovascular events in atrial fibrillation patients with CHA2DS2-VASc risk score of 1 and higher. Europace 2013; 15: 676-684. doi: 10.1093/europace/eus336
    [25]
    Chang CH, Lin JW, Chiu FC, et al. Effect of radiofrequency catheter ablation for atrial fibrillation on morbidity and mortality: a nationwide cohort study and propensity score analysis. Circ Arrhythm Electrophysiol 2014; 7: 76-82. doi: 10.1161/CIRCEP.113.000597
    [26]
    Friberg L, Tabrizi F, Englund A. Catheter ablation for atrial fibrillation is associated with lower incidence of stroke and death: data from Swedish health registries. Eur Heart J 2016; 37: 2478-2487. doi: 10.1093/eurheartj/ehw087
    [27]
    Saliba W, Schliamser JE, Lavi I, et al. Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: a propensity score-matched analysis. Heart Rhythm 2017; 14: 635-642. doi: 10.1016/j.hrthm.2017.02.001
    [28]
    Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019; 321: 1261-1274. doi: 10.1001/jama.2019.0693
    [29]
    Nademanee K, Amnueypol M, Lee F, et al. Benefits and risks of catheter ablation in elderly patients with atrial fibrillation. Heart Rhythm 2015; 12: 44-51. doi: 10.1016/j.hrthm.2014.09.049
    [30]
    Hunter RJ, McCready J, Diab I, et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 2012; 98: 48-53. doi: 10.1136/heartjnl-2011-300720
    [31]
    Yiin GS, Howard DP, Paul NL, et al. Age-specific incidence, outcome, cost, and projected future burden of atrial fibrillation-related embolic vascular events: a population-based study. Circulation 2014; 130: 1236-1244. doi: 10.1161/CIRCULATIONAHA.114.010942
    [32]
    Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272. doi: 10.1378/chest.09-1584
    [33]
    Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39: 1330-1393. doi: 10.1093/eurheartj/ehy136
    [34]
    Chao TF, Liu CJ, Lin YJ, et al. Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study. Circulation 2018; 138: 37-47. doi: 10.1161/CIRCULATIONAHA.117.031658
    [35]
    Alnsasra H, Haim M, Senderey AB, et al. Net clinical benefit of anticoagulant treatments in elderly patients with nonvalvular atrial fibrillation: experience from the real world. Heart Rhythm 2019; 16: 31-37. doi: 10.1016/j.hrthm.2018.08.016
    [36]
    Chang SS, Dong JZ, Ma CS, et al. Current status and time trends of oral anticoagulation use among Chinese patients with nonvalvular atrial fibrillation: the Chinese Atrial Fibrillation Registry Study. Stroke 2016; 47: 1803-1810. doi: 10.1161/STROKEAHA.116.012988
    [37]
    DeVore AD, Hellkamp AS, Becker RC, et al. Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace 2016; 18: 1135-1142. doi: 10.1093/europace/euv404
    [38]
    Joy PS, Gopinathannair R, Olshansky B. Effect of ablation for atrial fibrillation on heart failure readmission rates. Am J Cardiol 2017; 120: 1572-1577. doi: 10.1016/j.amjcard.2017.07.057
    [39]
    Mansour M, Heist EK, Agarwal R, et al. Stroke and cardiovascular events after ablation or antiarrhythmic drugs for treatment of patients with atrial fibrillation. Am J Cardiol 2018; 121: 1192-1199. doi: 10.1016/j.amjcard.2018.01.043
    [40]
    Di Biase L, Mohanty P, Mohanty S, et al. Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 2016; 133: 1637-1644. doi: 10.1161/CIRCULATIONAHA.115.019406
    [41]
    Prabhu S, Taylor AJ, Costello BT, et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J Am Coll Cardiol 2017; 70: 1949-1961. doi: 10.1016/j.jacc.2017.08.041
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(1)

    Article Metrics

    Article views (122) PDF downloads(18) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return